PMC10108845_01
Clinical, histological and immunofluorescent findings in patient 1: (a-c) Figurate and confluent psoriatic plaques with multiple tense blisters and crusted erosions on healthy and psoriatic skin; (d) histology from psoriatic plaque with abundant eosinophil infiltrate; (e) subepidermal clefting with abundant mixed infiltrate in papillary dermis and eosinophil predominance interstitially; (f) direct immunofluorescence with linear deposits of IgG along the BMZ in perilesional skin; (g) reduction of erythema, desquamation and blistering during secukinumab treatment.
fmed-10-1148660-g001.jpg
PMC10108845_03_fmed-10-1148660-g001.jpg
F1
Secukinumab at initial weekly administration of 300 mg during the first month and subsequent monthly application achieved complete and stable control of both skin disorders for the next 1.5 years (Figure 3b and Table 1).
PMC10108845_02
Clinical presentation of patient 2: (a) Flare of both psoriasis and BP while on reduced dose of methotrexate; (b) worsening of BP during secukinumab treatment.
fmed-10-1148660-g002.jpg
PMC10108845_02_fmed-10-1148660-g002.jpg
F2
BP (Figure 2a). Based on our previous experience, secukinumab was administered at a conventional regimen with a loading dose of 300 mg/weekly for 4 weeks. In the course of the first month of secukinumab application, worsening of BP was observed with aggravation of the subjective complaints and appearance of multiple new bullae on erythematous background, while psoriatic lesions healed almost completely (Figure 2b).
PMC10108845_03
Clinical, histological and immunofluorescent findings in patient 1: (a-c) Figurate and confluent psoriatic plaques with multiple tense blisters and crusted erosions on healthy and psoriatic skin; (d) histology from psoriatic plaque with abundant eosinophil infiltrate; (e) subepidermal clefting with abundant mixed infiltrate in papillary dermis and eosinophil predominance interstitially; (f) direct immunofluorescence with linear deposits of IgG along the BMZ in perilesional skin; (g) reduction of erythema, desquamation and blistering during secukinumab treatment.
fmed-10-1148660-g001.jpg
PMC10108845_03_fmed-10-1148660-g001.jpg
F1
Secukinumab at initial weekly administration of 300 mg during the first month and subsequent monthly application achieved complete and stable control of both skin disorders for the next 1.5 years (Figure 3b and Table 1).
Clinical presentation of patient 3: (a) Diffuse scaly erythema on the trunk and extremities with superimposed multiple tense vesicles and bullae on both healthy and psoriatic skin; (b) complete control of both psoriasis and BP during secukinumab treatment.
fmed-10-1148660-g003.jpg
PMC10108845_03_fmed-10-1148660-g003.jpg
F3
Dermatological examination upon admission revealed diffuse scaly erythema on the trunk and extremities with superimposed multiple tense vesicles and bullae on both healthy and psoriatic skin (Figure 3a). Secukinumab at initial weekly administration of 300 mg during the first month and subsequent monthly application achieved complete and stable control of both skin disorders for the next 1.5 years (Figure 3b and Table 1).